SI1673352T1 - Sulfoksiminsko substituirani pirimidini kot CDK-in/ali VEGF-inhibitorji, njihova priprava in uporaba kot zdravila - Google Patents
Sulfoksiminsko substituirani pirimidini kot CDK-in/ali VEGF-inhibitorji, njihova priprava in uporaba kot zdravilaInfo
- Publication number
- SI1673352T1 SI1673352T1 SI200431148T SI200431148T SI1673352T1 SI 1673352 T1 SI1673352 T1 SI 1673352T1 SI 200431148 T SI200431148 T SI 200431148T SI 200431148 T SI200431148 T SI 200431148T SI 1673352 T1 SI1673352 T1 SI 1673352T1
- Authority
- SI
- Slovenia
- Prior art keywords
- sulfoximine
- vegf
- inhibitors
- drugs
- production
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10349423A DE10349423A1 (de) | 2003-10-16 | 2003-10-16 | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| EP04790500A EP1673352B1 (de) | 2003-10-16 | 2004-10-12 | Sulfoximinsubstituierte pyrimidine als cdk- und/oder vegf-inhitoren, deren herstellung und verwendung als arzneimittel |
| PCT/EP2004/011661 WO2005037800A1 (de) | 2003-10-16 | 2004-10-12 | Sulfoximinsubstituierte pyrimidine als cdk- und/oder vegf-inhibitoren, deren herstellung und verwendung als arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1673352T1 true SI1673352T1 (sl) | 2009-08-31 |
Family
ID=34442222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200431148T SI1673352T1 (sl) | 2003-10-16 | 2004-10-12 | Sulfoksiminsko substituirani pirimidini kot CDK-in/ali VEGF-inhibitorji, njihova priprava in uporaba kot zdravila |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US8507510B2 (ru) |
| EP (1) | EP1673352B1 (ru) |
| JP (1) | JP4700006B2 (ru) |
| KR (1) | KR101117387B1 (ru) |
| CN (1) | CN1867553B (ru) |
| AR (1) | AR046119A1 (ru) |
| AT (1) | ATE427939T1 (ru) |
| AU (1) | AU2004281960B2 (ru) |
| BR (1) | BRPI0415421A (ru) |
| CA (1) | CA2542492C (ru) |
| CR (1) | CR8363A (ru) |
| CY (1) | CY1110058T1 (ru) |
| DE (2) | DE10349423A1 (ru) |
| DK (1) | DK1673352T3 (ru) |
| EC (1) | ECSP066568A (ru) |
| ES (1) | ES2324475T3 (ru) |
| GT (1) | GT200400206A (ru) |
| HK (1) | HK1093731A1 (ru) |
| HR (1) | HRP20090348T1 (ru) |
| IL (1) | IL174952A (ru) |
| JO (1) | JO2534B1 (ru) |
| ME (1) | ME00158B (ru) |
| MX (1) | MXPA06004091A (ru) |
| MY (1) | MY140291A (ru) |
| NO (1) | NO337290B1 (ru) |
| NZ (1) | NZ546510A (ru) |
| PE (1) | PE20050907A1 (ru) |
| PL (1) | PL1673352T3 (ru) |
| PT (1) | PT1673352E (ru) |
| RS (1) | RS51657B (ru) |
| RU (1) | RU2410378C2 (ru) |
| SI (1) | SI1673352T1 (ru) |
| TW (1) | TWI347844B (ru) |
| UA (1) | UA86041C2 (ru) |
| WO (1) | WO2005037800A1 (ru) |
| ZA (1) | ZA200603885B (ru) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002096888A1 (de) * | 2001-05-29 | 2002-12-05 | Schering Aktiengesellschaft | Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| EP1490354A1 (en) * | 2002-03-09 | 2004-12-29 | Astrazeneca AB | 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity |
| GB0205690D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| ATE451104T1 (de) | 2002-07-29 | 2009-12-15 | Rigel Pharmaceuticals Inc | Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen |
| US7157455B2 (en) | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
| PL1656372T3 (pl) | 2003-07-30 | 2013-08-30 | Rigel Pharmaceuticals Inc | Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym |
| DE10349423A1 (de) * | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| CA2566531A1 (en) | 2004-05-18 | 2005-12-15 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
| GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| BRPI0606318B8 (pt) | 2005-01-19 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, composição, e, uso de um composto |
| EP1705177A1 (en) * | 2005-03-23 | 2006-09-27 | Schering Aktiengesellschaft | N-aryl-sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents |
| EP1710246A1 (en) * | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
| WO2006133426A2 (en) | 2005-06-08 | 2006-12-14 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| US7745428B2 (en) | 2005-09-30 | 2010-06-29 | Astrazeneca Ab | Imidazo[1,2-A]pyridine having anti-cell-proliferation activity |
| AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US7705009B2 (en) | 2005-11-22 | 2010-04-27 | Hoffman-La Roche Inc. | 4-aminopyrimidine-5-thione derivatives |
| FR2894746B1 (fr) * | 2005-12-09 | 2008-06-13 | Ipanema Technologies Sa | Procede et dispositif de controle a distance de la congestion de flux mailles dans un reseau de telecommunication en mode paquet |
| DE102005062742A1 (de) * | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel |
| EP1803723A1 (de) * | 2006-01-03 | 2007-07-04 | Bayer Schering Pharma Aktiengesellschaft | (2,4,9-triaza-1(2,4)-pyrimidina-3(1,3)-benzenacyclononaphan-3^4-yl)-sulfoximid derivate als selektive inhibitoren der aurora kinase zur behandlung von krebs |
| ES2622493T3 (es) | 2006-02-24 | 2017-07-06 | Rigel Pharmaceuticals, Inc. | Composiciones y métodos para la inhibición de la ruta de JAK |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| DE102006027156A1 (de) | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | Sulfimide als Proteinkinaseinhibitoren |
| EP1878726A1 (en) * | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same |
| DE102006041382A1 (de) * | 2006-08-29 | 2008-03-20 | Bayer Schering Pharma Ag | Carbamoyl-Sulfoximide als Proteinkinaseinhibitoren |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| DE602007012363D1 (de) | 2006-10-19 | 2011-03-17 | Rigel Pharmaceuticals Inc | 2,4-pyridimediamon-derivate als hemmer von jak-kinasen zur behandlung von autoimmunerkrankungen |
| US8143410B2 (en) | 2006-11-16 | 2012-03-27 | Allergan, Inc. | Kinase inhibitors |
| US8558002B2 (en) * | 2006-11-16 | 2013-10-15 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
| WO2008061236A2 (en) * | 2006-11-16 | 2008-05-22 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
| EP2022785A1 (en) * | 2007-06-20 | 2009-02-11 | Bayer Schering Pharma Aktiengesellschaft | Alkynylpyrimidines as Tie2 kinase inhibitors |
| CA2712367C (en) * | 2008-01-17 | 2016-01-19 | Bayer Schering Pharma Aktiengesellschaft | Sulphoximine-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicaments |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| NZ589315A (en) | 2008-04-16 | 2012-11-30 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors |
| KR101773313B1 (ko) | 2008-04-16 | 2017-08-31 | 포톨라 파마슈티컬스, 인코포레이티드 | ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드 |
| BRPI0910668A2 (pt) | 2008-04-22 | 2019-09-24 | Portola Pharmaceutiacals Inc | inibidores de proteína quinases |
| EP2161259A1 (de) * | 2008-09-03 | 2010-03-10 | Bayer CropScience AG | 4-Halogenalkylsubstituierte Diaminopyrimidine als Fungizide |
| EP2179991A1 (de) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| EP2179993A1 (de) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfoxidsubstituierte Anilinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| EP2179992A1 (de) | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| DE102009001438A1 (de) | 2009-03-10 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Carbonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| DE102009015070A1 (de) | 2009-03-30 | 2010-10-14 | Bayer Schering Pharma Aktiengesellschaft | Aminocabonylamino-substituierte Anilino-Pyrimidinderivate als Tyk-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| WO2011017178A1 (en) * | 2009-07-28 | 2011-02-10 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| DE102010014427A1 (de) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| DE102010014426A1 (de) * | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| US8354420B2 (en) | 2010-06-04 | 2013-01-15 | Genentech, Inc. | Aminopyrimidine derivatives as LRRK2 inhibitors |
| DE102010046720A1 (de) | 2010-09-23 | 2012-03-29 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung |
| CN103282352B (zh) | 2010-11-01 | 2016-08-10 | 波托拉医药品公司 | 作为syk调节剂的苯甲酰胺类和烟酰胺类 |
| WO2012061415A1 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
| WO2012061428A2 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
| PL3124483T3 (pl) | 2010-11-10 | 2020-03-31 | Genentech, Inc. | Pirazolowo-aminopirymidynowe pochodne jako modulatory LRRK2 |
| TWI555737B (zh) | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| EP2527332A1 (en) | 2011-05-24 | 2012-11-28 | Bayer Intellectual Property GmbH | 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors |
| EP2755948B1 (en) * | 2011-09-16 | 2016-05-25 | Bayer Intellectual Property GmbH | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group |
| JP6174586B2 (ja) | 2011-09-23 | 2017-08-02 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換イミダゾピリダジン |
| WO2013059634A1 (en) | 2011-10-20 | 2013-04-25 | The Regents Of The University Of California | Use of cdk9 inhibitors to reduce cartilage degradation |
| MX363551B (es) | 2011-11-23 | 2019-03-27 | Portola Pharmaceuticals Inc Star | Compuestos derivados de pirazina como inhibidores de cinasa. |
| JP2015510910A (ja) | 2012-03-21 | 2015-04-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 特定の腫瘍の処置のための、（ｒｓ）−ｓ−シクロプロピル−ｓ−（４−｛［４−｛［（１ｒ，２ｒ）−２−ヒドロキシ−１−メチルプロピル］オキシ｝−５−（トリフルオロメチル）ピリミジン−２−イル］アミノ｝フェニル）スルホキシミドの使用 |
| WO2014058921A2 (en) | 2012-10-08 | 2014-04-17 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| CN104854091B (zh) | 2012-10-18 | 2018-04-03 | 拜耳药业股份公司 | 含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物 |
| CN105283453B (zh) | 2012-10-18 | 2018-06-22 | 拜耳药业股份公司 | 含砜基的n-(吡啶-2-基)嘧啶-4-胺衍生物 |
| TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之ｎ－（吡啶－２－基）嘧啶－４－胺衍生物 |
| KR102242871B1 (ko) * | 2012-11-15 | 2021-04-20 | 바이엘 파마 악티엔게젤샤프트 | 술폭시민 기를 함유하는 5-플루오로-n-(피리딘-2-일)피리딘-2-아민 유도체 |
| US9499492B2 (en) * | 2012-11-15 | 2016-11-22 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group |
| WO2014173815A1 (en) | 2013-04-23 | 2014-10-30 | Bayer Pharma Aktiengesellschaft | Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours |
| CA2916103A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Diaminoheteroaryl substituted pyrazoles |
| JP6371385B2 (ja) | 2013-07-04 | 2018-08-08 | バイエル ファーマ アクチエンゲゼルシャフト | スルホキシイミン置換５−フルオロ−ｎ−（ピリジン−２−イル）ピリジン−２−アミン誘導体およびそのｃｄｋ９キナーゼ阻害薬としての使用 |
| CN105764893A (zh) | 2013-10-30 | 2016-07-13 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| CN105916850B (zh) * | 2013-12-12 | 2020-03-20 | 阿勒根公司 | 作为激酶抑制剂的取代的二烷基(氧撑)-λ4-硫烷亚基烟酰胺衍生物 |
| CN106232596A (zh) | 2014-03-13 | 2016-12-14 | 拜耳医药股份有限公司 | 含有砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物 |
| US9790189B2 (en) | 2014-04-01 | 2017-10-17 | Bayer Pharma Aktiengesellschaft | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group |
| CU24399B1 (es) | 2014-04-11 | 2019-04-04 | Bayer Pharma AG | Nuevos compuestos macrocíclicos en calidad de inhibidores de cdk9, un proceso para su preparación y los compuestos intermediarios útiles en la preparación de estos compuestos |
| TWI700283B (zh) | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| JP6930913B2 (ja) | 2014-10-14 | 2021-09-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 炎症を阻害するためのｃｄｋ９及びｂｒｄ４阻害剤の使用法 |
| CN107001341B (zh) | 2014-10-16 | 2020-08-07 | 拜耳医药股份有限公司 | 含有磺亚胺基的氟化苯并呋喃基-嘧啶衍生物 |
| WO2016059011A1 (en) | 2014-10-16 | 2016-04-21 | Bayer Pharma Aktiengesellschaft | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group |
| EP3356373B1 (en) | 2015-09-29 | 2020-02-19 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic sulfondiimine compounds |
| WO2017060167A1 (en) | 2015-10-08 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Novel modified macrocyclic compounds |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| WO2018177889A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| PL3601253T3 (pl) | 2017-03-28 | 2022-01-17 | Bayer Aktiengesellschaft | Nowe hamujące ptefb związki makrocykliczne |
| KR101936054B1 (ko) | 2017-06-23 | 2019-01-11 | 한국과학기술연구원 | 항염증 활성을 가지는 6-페녹시피리미딘 유도체, 이의 제조방법 및 이를 활성성분으로 하는 약학 조성물 |
| JOP20200196A1 (ar) | 2018-02-13 | 2020-08-13 | Bayer Ag | استخدام 5-فلورو-4-(4-فلورو-2-مثوكسي فنيل)- n-{4-[(s-مثيل كبريتون ايميدويل) مثيل] بيريدين-2-يل} بيريدين -2-امين لمعالجة ليمفومة الخلايا البائية الكبيرة المنتشرة |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| WO2022266394A1 (en) * | 2021-06-18 | 2022-12-22 | The Trustees Of Columbia University In The City Of New York | Novel isomerohydrolase inhibitor for treatment of atrophic form of age-related macular degeneration and stargardt disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187189A (en) | 1991-01-22 | 1993-02-16 | American Home Products Corporation | S-aminoalkyl-s-arylsulfoximines as antiarrhythmic agents |
| US5902817A (en) * | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
| GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| JP2000232898A (ja) | 1999-02-17 | 2000-08-29 | Kyowa Medex Co Ltd | 物質の定量方法および定量試薬 |
| GB9905075D0 (en) * | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004888D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| WO2002096888A1 (de) * | 2001-05-29 | 2002-12-05 | Schering Aktiengesellschaft | Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel |
| GB0113041D0 (en) * | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| EP1483260A1 (de) * | 2002-03-11 | 2004-12-08 | Schering Aktiengesellschaft | Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel |
| US7288547B2 (en) * | 2002-03-11 | 2007-10-30 | Schering Ag | CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents |
| RS20060097A (en) * | 2002-12-20 | 2008-11-28 | Pfizer Products Inc., | Pyrimidine derivatives for the treatment of abnormal cell growth |
| DE10349423A1 (de) * | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
-
2003
- 2003-10-16 DE DE10349423A patent/DE10349423A1/de not_active Ceased
-
2004
- 2004-09-30 JO JO2004138A patent/JO2534B1/en active
- 2004-10-12 DE DE502004009330T patent/DE502004009330D1/de not_active Expired - Lifetime
- 2004-10-12 MX MXPA06004091A patent/MXPA06004091A/es active IP Right Grant
- 2004-10-12 PL PL04790500T patent/PL1673352T3/pl unknown
- 2004-10-12 EP EP04790500A patent/EP1673352B1/de not_active Expired - Lifetime
- 2004-10-12 SI SI200431148T patent/SI1673352T1/sl unknown
- 2004-10-12 CN CN2004800304726A patent/CN1867553B/zh not_active Expired - Fee Related
- 2004-10-12 RS YU20060264A patent/RS51657B/en unknown
- 2004-10-12 BR BRPI0415421-5A patent/BRPI0415421A/pt active Search and Examination
- 2004-10-12 ES ES04790500T patent/ES2324475T3/es not_active Expired - Lifetime
- 2004-10-12 RU RU2006116466/04A patent/RU2410378C2/ru not_active IP Right Cessation
- 2004-10-12 US US12/095,947 patent/US8507510B2/en not_active Expired - Fee Related
- 2004-10-12 UA UAA200605171A patent/UA86041C2/ru unknown
- 2004-10-12 AU AU2004281960A patent/AU2004281960B2/en not_active Ceased
- 2004-10-12 DK DK04790500T patent/DK1673352T3/da active
- 2004-10-12 AT AT04790500T patent/ATE427939T1/de active
- 2004-10-12 ME MEP-2008-158A patent/ME00158B/me unknown
- 2004-10-12 NZ NZ546510A patent/NZ546510A/en not_active IP Right Cessation
- 2004-10-12 PT PT04790500T patent/PT1673352E/pt unknown
- 2004-10-12 JP JP2006534714A patent/JP4700006B2/ja not_active Expired - Fee Related
- 2004-10-12 CA CA2542492A patent/CA2542492C/en not_active Expired - Fee Related
- 2004-10-12 WO PCT/EP2004/011661 patent/WO2005037800A1/de active Application Filing
- 2004-10-13 TW TW093130948A patent/TWI347844B/zh not_active IP Right Cessation
- 2004-10-13 GT GT200400206A patent/GT200400206A/es unknown
- 2004-10-15 AR ARP040103755A patent/AR046119A1/es unknown
- 2004-10-15 MY MYPI20044268A patent/MY140291A/en unknown
- 2004-10-15 PE PE2004001003A patent/PE20050907A1/es not_active Application Discontinuation
- 2004-10-18 US US10/966,098 patent/US7338958B2/en not_active Expired - Fee Related
-
2006
- 2006-04-11 IL IL174952A patent/IL174952A/en not_active IP Right Cessation
- 2006-04-25 CR CR8363A patent/CR8363A/es unknown
- 2006-05-12 EC EC2006006568A patent/ECSP066568A/es unknown
- 2006-05-15 NO NO20062174A patent/NO337290B1/no not_active IP Right Cessation
- 2006-05-15 KR KR1020067009424A patent/KR101117387B1/ko not_active IP Right Cessation
- 2006-05-15 ZA ZA200603885A patent/ZA200603885B/en unknown
- 2006-12-29 HK HK06114263.5A patent/HK1093731A1/xx not_active IP Right Cessation
-
2009
- 2009-06-15 HR HR20090348T patent/HRP20090348T1/hr unknown
- 2009-07-08 CY CY20091100726T patent/CY1110058T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1673352T1 (sl) | Sulfoksiminsko substituirani pirimidini kot CDK-in/ali VEGF-inhibitorji, njihova priprava in uporaba kot zdravila | |
| IL168102A0 (en) | Chk-, pdk-and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | |
| EG25011A (en) | Amino-piperidin-1-yl-xanthines, the production thereof and the use of the same as medicaments. | |
| IL173204A0 (en) | Novel cyanopyrrolidides, methods for the production thereof, and use of the same as medicaments | |
| TWI347201B (en) | Pharmaceutical products,uses thereof and methods for preparing the same | |
| AU2003293757A1 (en) | Novel substituted imidazo-pyridinones and imidazo-pyridazeiones, the production and use thereof as medicaments | |
| IL178334A0 (en) | Selected cgrp antagonists, methods for the production thereof and their use as medicaments | |
| IL181012A0 (en) | Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments | |
| IL174405A0 (en) | 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics | |
| IL190423A0 (en) | Selected cgrp antagonists , methods for the production thereof and their use as medicaments | |
| IL175245A0 (en) | Thiozolidinones, production and use thereof as medicaments | |
| IL183395A0 (en) | Meta-substituted thiazolidinones, the production thereof and their use as medicaments | |
| IL189497A0 (en) | Selected cgrp antagonists, methods for the production thereof and their use as medicaments | |
| PL394604A1 (pl) | Pochodna winyloazacykloalkanowa, jej zastosowanie oraz kompozycja farmaceutyczna | |
| IL169318A0 (en) | Pyrimidines, methods for the production thereof, and use thereof | |
| IL174975A0 (en) | 2-phenyl-benzofuran derivatives, method for the production thereof and their use | |
| HK1100946A1 (en) | 1-a-HALO-2,2-DIFLUORO-2-DEOXY-D-RIBOFURANOSE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | |
| ZA200705782B (en) | Meta-substituted thiazolidinones, the production thereof and their use as medicaments | |
| IL173447A0 (en) | Substituted benzoylureido-o-benzoylamides, method for the production thereof and use of the same | |
| IL157793A0 (en) | Caloporoside derivatives, methods for the production thereof and their use | |
| EP1829860A4 (en) | 9,10-SECOPREGNANDERIVAT AND MEDICINE | |
| EP1781678A4 (en) | 1 -? - HALOGEN-2,2-DIFLUOR-2-DESOXY-D-RIBOFURANOSEDERIVATE AND PROCESS FOR THE PRODUCTION THEREOF | |
| AU2003216893A1 (en) | Phenethylacrylamide, methods for the production thereof and agents containing the same | |
| GB0315201D0 (en) | Substituted organopolysiloxanes, methods for the production and use thereof | |
| AU2003261574A1 (en) | The dna-antibody and the uses thereof |